Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

While Merck faces the inevitable Keytruda patent cliff in 2028, ... MK-0616, an investigational oral drug for lowering LDL cholesterol, is designed to be the first oral PCSK9 inhibitor.

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

“We want to democratize the PCSK9 pathway, because that is the most potent way to lower LDL cholesterol,” Merck Research Laboratories President Dean Li said at an investor conference in late May.

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

RAHWAY, N.J., June 09, 2025--Merck Announces Positive Topline Results from Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia ...

Merck, which is evaluating the safety and efficacy of enlicitide for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin, said the Phase 3 studies met ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist. Geopolitical tensions, Fed uncertainty, and fast-moving headlines are driving July volatility.

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...